Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Non-Current Assets (2016 - 2025)

IGC Pharma (IGC) has disclosed Non-Current Assets for 15 consecutive years, with $7.7 million as the latest value for Q3 2025.

  • Quarterly Non-Current Assets rose 26.47% to $7.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Sep 2025, up 26.47% year-over-year, with the annual reading at $5.9 million for FY2025, 5.58% down from the prior year.
  • Non-Current Assets for Q3 2025 was $7.7 million at IGC Pharma, up from $5.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $12.4 million in Q1 2021, with the low at $5.8 million in Q2 2025.
  • Average Non-Current Assets over 5 years is $9.3 million, with a median of $10.6 million recorded in 2023.
  • The sharpest move saw Non-Current Assets tumbled 42.15% in 2024, then rose 26.47% in 2025.
  • Over 5 years, Non-Current Assets stood at $12.1 million in 2021, then fell by 11.08% to $10.7 million in 2022, then dropped by 28.37% to $7.7 million in 2023, then decreased by 21.48% to $6.0 million in 2024, then rose by 28.41% to $7.7 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $7.7 million, $5.8 million, and $5.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.